This page contains regularly updated information on Realm Therapeutics securities and the Company's most significant shareholders. Realm Therapeutics is traded on Nasdaq. There are no restrictions on the trading of Realm Therapeutics' shares

As of 27 February 2019
Number of securities in issue: 116,561,917 10p Ords
There are no shares held in treasury.
Percentage of Securities not in public hands: 35.62%

As of 27 February 2019, the following shareholders held interests in excess of 3% of ordinary share capital.

  Amount % Holding
OrbiMed 25,537,109 21.91%
BVF Partners LP 15,322,266 13.15%
BAVARIA Industries Group AG 6,944,948 5.96%
Abingworth BioEquities Master Fund Ltd. 6,384,277 5.48%
Sussex Trading Company Limited 6,148,880 5.28%
Daniel Hegglin 5,849,091 5.02%
Oracle Management Limited 5,410,196 4.64%
Kanton Services Limited 4,629,196 3.97%
Polar Capital Funds Plc 3,500,000 3.00%
     

Directors' Information

  Amount % Holding
Mr. Spicer 273,930 0.24%
Mr. Martin* 248,115 0.21%
Mr. Birkett 92,686 0.08%
Ms. Thorell* 50,000 0.04%
Dr. Gergel - 0.00%
Dr. Gill - 0.00%
Mr. Zweifach - 0.00%

* Executive Director

Search Investor Relations